New laboratory data reveal that vapour from a novel hybrid tobacco heating product (THP) iFuse and two standard THPs produced little or no effect on human cells in biological testing.
'Our results suggest that these standard THPs and our novel hybrid product have the potential to reduce smoking-related disease risks when compared with cigarette smoking,' says Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco. 'However, further pre-clinical and clinical research is required to substantiate conclusive risk reduction of these products.'
A series of lab-based biological studies were used to assess and compare the toxicological and biological effects of exposure to vapour from the hybrid iFuse, two different standard THPs, and smoke from a 3R4F reference cigarette. The tests looked at the general health of the cells, mutations and damage to DNA, tumour promotion, oxidative stress and wound repair, all of which are involved in development of many smoking-related diseases.
'Our results suggest that these standard THPs and our novel hybrid product have the potential to reduce smoking-related disease risks when compared with cigarette smoking,' says Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco. 'However, further pre-clinical and clinical research is required to substantiate conclusive risk reduction of these products.'
A series of lab-based biological studies were used to assess and compare the toxicological and biological effects of exposure to vapour from the hybrid iFuse, two different standard THPs, and smoke from a 3R4F reference cigarette. The tests looked at the general health of the cells, mutations and damage to DNA, tumour promotion, oxidative stress and wound repair, all of which are involved in development of many smoking-related diseases.
on Mon, 06/05/2017 - 23:45 admin
